A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma

Clinical article

View More View Less
  • 1 Departments of Radiation Oncology,
  • 2 Neuro-Oncology,
  • 3 Neurosurgery, and
  • 4 Pathology, New York University Langone Medical Center, New York, New York; and
  • 5 Atlantic Health System, Overlook Hospital, Summit, New Jersey
Restricted access

Purchase Now

USD  $45.00

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $505.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $600.00
Print or Print + Online

Object

The presence of angiogenesis is a hallmark of glioblastoma (GBM). Vascular endothelial growth factor (VEGF), which drives angiogenesis, provides an additional target for conventional therapy. The authors conducted a prospective clinical trial to test the effectiveness of bevacizumab, an inhibitor of VEGF, in newly diagnosed GBM.

Methods

From 2006 through 2010, 51 eligible patients with newly diagnosed GBM were treated with involved-field radiation therapy and concomitant temozolomide (75 mg/m2 daily for 42 days) along with bevacizumab (10 mg/kg every 2 weeks), starting 29 days after surgery. This was followed by 6 cycles of adjuvant temozolomide therapy (150 mg/m2 on Days 1–7 of a 28-day cycle) with bevacizumab administered at 10 mg/kg on Days 8 and 22 of each 28-day cycle.

Results

The 6- and 12-month progression-free survival (PFS) rates were 85.1% and 51%, respectively. The 12- and 24-month overall survival (OS) rates were 85.1% and 42.5%, respectively. Grade III/IV toxicities were noted in 10 patients (19.6%). No treatment-related deaths were observed. Asymptomatic intracranial bleeding was noted in 5 patients.

Conclusions

The addition of bevacizumab to conventional therapy in newly diagnosed GBM appears to improve both PFS and OS in patients with newly diagnosed GBM, with acceptable morbidity. A shift toward diffuse relapse was noted in a significant number of patients. Ongoing Phase III clinical trials will show the true benefit of this antiangiogenic approach.

Abbreviations used in this paper: EORTC = European Organization for Research and Treatment of Cancer; GBM = glioblastoma; KPS = Karnofsky Performance Scale; OS = overall survival; PFS = progression-free survival; UCLA = University of California, Los Angeles; VEGF = vascular endothelial growth factor.

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $505.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $600.00

Contributor Notes

Address correspondence to: Ashwatha Narayana, M.D., Department of Radiation Oncology, New York University Langone Medical Center, 550 1st Avenue, New York, New York 10016. email: ashwatha.narayana@nyumc.org.

Please include this information when citing this paper: published online October 28, 2011; DOI: 10.3171/2011.9.JNS11656.

  • 1

    Barcellos-Hoff MH, , Newcomb EW, , Zagzag D, & Narayana A: Therapeutic targets in malignant glioblastoma microenvironment. Semin Radiat Oncol 19:163170, 2009

    • Search Google Scholar
    • Export Citation
  • 2

    Duda DG, , Jain RK, & Willett CG: Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers. J Clin Oncol 25:40334042, 2007

    • Search Google Scholar
    • Export Citation
  • 3

    Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 285:11821186, 1971

  • 4

    Friedman HS, , Prados MD, , Wen PY, , Mikkelsen T, , Schiff D, & Abrey LE, : Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:47334740, 2009

    • Search Google Scholar
    • Export Citation
  • 5

    Grossman SA, , Ye X, , Piantadosi S, , Desideri S, , Nabors LB, & Rosenfeld M, : Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin Cancer Res 16:24432449, 2010

    • Search Google Scholar
    • Export Citation
  • 6

    Gruber ML, , Raza S, , Gruber D, & Narayana A: Bevacizumab in combination with radiotherapy plus concomitant and adjuvant temozolomide for newly diagnosed glioblastoma: update progression-free survival, overall survival, and toxicity. ASCO Meeting Abstracts 27:2017, 2009

    • Search Google Scholar
    • Export Citation
  • 7

    Iwamoto FM, , Abrey LE, , Beal K, , Gutin PH, , Rosenblum MK, & Reuter VE, : Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology 73:12001206, 2009

    • Search Google Scholar
    • Export Citation
  • 8

    Jain RK: Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7:987989, 2001

  • 9

    Jain RK, , di Tomaso E, , Duda DG, , Loeffler JS, , Sorensen AG, & Batchelor TT: Angiogenesis in brain tumours. Nat Rev Neurosci 8:610622, 2007

    • Search Google Scholar
    • Export Citation
  • 10

    Kreisl TN, , Kim L, , Moore K, , Duic P, , Royce C, & Stroud I, : Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27:740745, 2009

    • Search Google Scholar
    • Export Citation
  • 11

    Lai A, , Tran A, , Nghiemphu PL, , Pope WB, , Solis OE, & Selch M, : Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 29:142148, 2011

    • Search Google Scholar
    • Export Citation
  • 12

    Lamszus K, , Ulbricht U, , Matschke J, , Brockmann MA, , Fillbrandt R, & Westphal M: Levels of soluble vascular endothelial growth factor (VEGF) receptor 1 in astrocytic tumors and its relation to malignancy, vascularity, and VEGF-A. Clin Cancer Res 9:13991405, 2003

    • Search Google Scholar
    • Export Citation
  • 13

    Lee CG, , Heijn M, , di Tomaso E, , Griffon-Etienne G, , Ancukiewicz M, & Koike C, : Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 60:55655570, 2000

    • Search Google Scholar
    • Export Citation
  • 14

    Miyagami M, & Katayama Y: Angiogenesis of glioma: evaluation of ultrastructural characteristics of microvessels and tubular bodies (Weibel-Palade) in endothelial cells and immunohistochemical findings with VEGF and p53 protein. Med Mol Morphol 38:3642, 2005

    • Search Google Scholar
    • Export Citation
  • 15

    Narayana A, , Golfinos JG, , Fischer I, , Raza S, , Kelly P, & Parker E, : Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma. Int J Radiat Oncol Biol Phys 72:383389, 2008

    • Search Google Scholar
    • Export Citation
  • 16

    Narayana A, , Kelly P, , Golfinos J, , Parker E, , Johnson G, & Knopp E, : Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. Clinical article. J Neurosurg 110:173180, 2009

    • Search Google Scholar
    • Export Citation
  • 17

    Narayana A, , Kunnakkat SD, , Medabalmi P, , Golfinos J, , Parker E, & Knopp E, : Change in pattern of relapse after antiangiogenic therapy in high-grade glioma. Int J Radiat Oncol Biol Phys [epub ahead of print] 2010

    • Search Google Scholar
    • Export Citation
  • 18

    Narayana A, , Recht L, & Gutin PH, Central Nervous System Tumors. Hoppe RT, , Philips TL, & Roach M: Textbook of Radiation Oncology Philadelphia, Saunders, 2010. 421432

    • Search Google Scholar
    • Export Citation
  • 19

    Nghiemphu PL, , Liu W, , Lee Y, , Than T, , Graham C, & Lai A, : Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology 72:12171222, 2009

    • Search Google Scholar
    • Export Citation
  • 20

    Norden AD, , Young GS, , Setayesh K, , Muzikansky A, , Klufas R, & Ross GL, : Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70:779787, 2008

    • Search Google Scholar
    • Export Citation
  • 21

    Nowicki MO, , Dmitrieva N, , Stein AM, , Cutter JL, , Godlewski J, & Saeki Y, : Lithium inhibits invasion of glioma cells; possible involvement of glycogen synthase kinase-3. Neurooncol 10:690699, 2008

    • Search Google Scholar
    • Export Citation
  • 22

    Stupp R, , Mason WP, , van den Bent MJ, , Weller M, , Fisher B, & Taphoorn MJB, : Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987996, 2005

    • Search Google Scholar
    • Export Citation
  • 23

    Vredenburgh JJ, , Desjardins A, , Herndon JE Jr, , Dowell JM, , Reardon DA, & Quinn JA, : Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13:12531259, 2007

    • Search Google Scholar
    • Export Citation
  • 24

    Willett CG, , Boucher Y, , di Tomaso E, , Duda DG, , Munn LL, & Tong RT, : Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10:145147, 2004

    • Search Google Scholar
    • Export Citation
  • 25

    Zagzag D, , Amirnovin R, , Greco MA, , Yee H, , Holash J, & Wiegand SJ, : Vascular apoptosis and involution in gliomas precede neovascularization: a novel concept for glioma growth and angiogenesis. Lab Invest 80:837849, 2000

    • Search Google Scholar
    • Export Citation

Metrics

All Time Past Year Past 30 Days
Abstract Views 908 346 9
Full Text Views 201 23 0
PDF Downloads 153 11 0
EPUB Downloads 0 0 0